1
|
Pérez-Fernández R, Cazanga V, Jeldres JA, Silva PP, Riquelme J, Quiroz F, Palma C, Carretta MD, Burgos RA. Plasma and tissue disposition of florfenicol in Escherichia coli lipopolysaccharide-induced endotoxaemic sheep. Xenobiotica 2016; 47:408-415. [PMID: 27378216 DOI: 10.1080/00498254.2016.1195522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
1. The purpose of this study was to understand the effects of the acute inflammatory response (AIR) induced by Escherichia coli lipopolysaccharide (LPS) on florfenicol (FFC) and FFC-amine (FFC-a) plasma and tissue concentrations. 2. Ten Suffolk Down sheep, 60.5 ± 4.7 kg, were distributed into two experimental groups: group 1 (LPS) treated with three intravenous doses of 1 μg/kg bw of LPS at 24, 16, and 0.75 h (45 min) before FFC treatment; group 2 (Control) was treated with saline solution (SS) in parallel to group 1. An IM dose of 20 mg FFC/kg was administered at 0.75 h after the last injection of LPS or SS. Blood and tissue samples were taken after FFC administration. 3. The plasma AUC0-4 h values of FFC were higher (p = 0.0313) in sheep treated with LPS (21.8 ± 2.0 μg·min/mL) compared with the control group (12.8 ± 2.3 μg·min/mL). Lipopolysaccharide injections increased FFC concentrations in kidneys, spleen, and brain. Low levels of plasma FFC-a were observed in control sheep (Cmax = 0.14 ± 0.01 μg/mL) with a metabolite ratio (MR) of 4.0 ± 0.87%. While in the LPS group, Cmax increased slightly (0.25 ± 0.01 μg/mL), and MR decreased to 2.8 ± 0.17%. 4. The changes observed in the plasma and tissue concentrations of FFC were attributed to the pathophysiological effects of LPS on renal hemodynamics that modified tissue distribution and reduced elimination of the drug.
Collapse
Affiliation(s)
- Rubén Pérez-Fernández
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Victoria Cazanga
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Jessie Ana Jeldres
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Pedro P Silva
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - José Riquelme
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Fernando Quiroz
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Cristina Palma
- a Laboratorio de Farmacología , Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias, Universidad de Concepción , Chillán , Chile and
| | - Maria D Carretta
- b Instituto de Farmacología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile , Valdivia , Chile
| | - Rafael A Burgos
- b Instituto de Farmacología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile , Valdivia , Chile
| |
Collapse
|
2
|
Dhuria S, Einolf H, Mangold J, Sen S, Gu H, Wang L, Cameron S. Time-Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects. J Clin Pharmacol 2013; 53:642-53. [DOI: 10.1002/jcph.79] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Accepted: 02/21/2013] [Indexed: 12/18/2022]
Affiliation(s)
| | - Heidi Einolf
- Novartis Institutes for Biomedical Research; East Hanover, NJ; USA
| | - James Mangold
- Novartis Institutes for Biomedical Research; East Hanover, NJ; USA
| | - Suman Sen
- Novartis Pharmaceuticals Corporation; East Hanover, NJ; USA
| | - Helen Gu
- Novartis Institutes for Biomedical Research; East Hanover, NJ; USA
| | - Lai Wang
- Novartis Institutes for Biomedical Research; East Hanover, NJ; USA
| | - Scott Cameron
- Novartis Pharmaceuticals Corporation; Cambridge, MA; USA
| |
Collapse
|
3
|
Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008; 4:1537-49. [DOI: 10.1517/17425250802525496] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|